

10/511661

REC'D 24 JUL 2003
WIPO PCT

18 OCT 2004

P1 1040123

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

July 17, 2003

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/391,361

FILING DATE: June 24, 2002

RELATED PCT APPLICATION NUMBER: PCT/US03/19393

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

H. Phillips
H. PHILLIPS
Certifying Officer

PRIORITY
DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

06/29/02
JC963 U.S. PTO

06-26-02 60391361 1162412

SUBSTITUTE for Provisional Application for Patent Cover Sheet PTO/SB/16 (10-01)
Approved for use through 10/31/2002 OMB 0651-0032
U S Patent and Trademark Office, U S DEPARTMENT OF COMMERCE

PROVISIONAL APPLICATION FOR PATENT COVER SHEET A/PROV

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

DOCKET NUMBER

21058P\

JC979 U.S. PTO 60391361
06/24/02


INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname	Residence (City and either State or Foreign Country)		
Thomas F. Conrad P. Matthew J. Mary Ann		Walsh Dorn Wyvrett Powles	Watchung, New Jersey Plainfield, New Jersey Mountainside, New Jersey Freehold, New Jersey		
<input type="checkbox"/> Additional inventors are being named on the separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
NOVEL AMINOALKYLPHENOL ANTIMALARIAL AGENTS					
CORRESPONDENCE ADDRESS					
Direct all Correspondence to: Merck & Co., Inc. Patent Department - RY60-30 P.O. Box 2000 Rahway					
<input checked="" type="checkbox"/> Customer Number 000210					
STATE	New Jersey	ZIP CODE	07065	COUNTRY	U.S.A.
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification <i>Number of Pages</i>		41	<input type="checkbox"/> CD(s), Number <input type="checkbox"/> Other (specify)		
<input type="checkbox"/> Drawing(s) <i>Number of Sheets</i>					
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)					
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 13-2755				FILING FEE AMOUNT (\$)	\$160.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

No.

Yes, the name of the U.S. Government agency and the Government contract number are: _____

Respectfully submitted,

SIGNATURE 

TYPED or PRINTED NAME **Sylvia A. Ayler**

TELEPHONE **732-594-4909**

Date **06/24/2002**


REGISTRATION NO.
(if appropriate) **36,436**

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT **June 24, 2002**

EXPRESS MAIL NO. **EL523910873US**

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

MAILED BY 

DATE **June 24, 2002**

In Duplicate

Computer generated form "Transmittal Form-PV" (Application Filing Folder) Merck & Co., Inc., 10/05/2001

21058PV

TITLE OF THE INVENTION

AMINOALKYLPHENOLS, METHODS OF USING AND MAKING THE SAME

BACKGROUND OF THE INVENTION

5 Historically, malaria infections were controlled with quinoline-based alkaloids from the cinchona tree, particularly quinine. Insufficient supplies of quinine and the need to protect troops fighting in malaria-endemic regions fueled researchers to discover synthetic quinoline-based antimalarial agents. This effort led to a series of antimalarial compounds including chloroquine which has been the mainstay of
10 antimalarial therapy since its introduction in 1945. Parallel medicinal chemistry efforts in the 1940s led to clinical evaluation of several phenolic Mannich bases as potential malarial agents.

15 However, the emergence of drug resistant strains of *Plasmodium* has caused many of the safest and least expensive antimalarial drugs to lose their effectiveness in many areas of the world. Therefore, there is a continued need to discover and develop antimalarial agents that are effective against new and old strains of *Plasmodium*.

20 The present invention relates to aminoalkylphenols, compositions containing an aminoalkylphenol as the active ingredient and methods of treating malaria. The compounds of this invention are antiprotozoal agents effective *in vivo* and *in vitro* against protozoa of the genus *Plasmodium* (*P. falciparum*, *P. bergei*, etc.,), the infectious agent responsible for malaria. The compounds of this invention are phenolic Mannich base derivatives, a class of chemical substances that have been intensely studied for many years for their antimalarial properties. See Burckhalter,
25 J.H., et al., *J. Am. Chem. Soc.*, 1946 Vol. 68, 1894-1901, and 1948, Vol. 70, 1363-1373, Duncan, W.G., et al., *J. Med. Chem.* 1969, 12, 711-112, and F.Y. Wiselogle, Ed.; *Survey of Antimalarial Drugs*, 1941-1945, Vols. I and II, Edwards Bros., Ann Arbor, MI. Aminoalkylphenols are also discussed U.S. Patent No. 3,794,734, issued February 26, 1974 and Stokker, G.E., et al., *J. Med. Chem.* 1980, 23, 1414-27.

30

SUMMARY OF THE INVENTION

The present invention relates to Mannich base antimalarial aminoalkylphenol compounds and their use against protozoa of the genus *Plasmodium*, particularly emerging strains of drug-resistant *Plasmodia*. This

21058PV

invention further relates to compositions containing such compounds and a process for making the compounds. This and other aspects of the invention are realized upon review of the entire specification.

5

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention there are disclosed aminoalkylphenol compounds having structural formula I:



10

wherein,

R5, R1a and R1 independently are hydrogen, C1-6 alkyl, halo, C1-6 alkoxy, C3-10 cycloalkyl, C6-10 aryl, and trihalovinyl, said aryl optionally substituted with 1-3 groups of Ra;

R2 is hydrogen, C1-6 alkyl, and C3-10 cycloalkyl; taken together with any intervening atoms can form a 3 to 7 membered carbocyclic or heterocyclic ring saturated or unsaturated, said heterocyclic ring containing 1-2 heteroatoms independently chosen from O, C(O), S, SO, SO₂, N, or NR2a and optionally substituted by 1-3 Ra groups;

R2a is hydrogen, and C1-6 alkyl;

R3 and R3a are independently hydrogen, halo, C1-6 alkyl, C3-10 cycloalkyl, and C6-10 aryl, said aryl and alkyl optionally substituted with 1-3 groups of Ra; or

R3 and R3a taken together with any intervening atoms can form a 3 to 7 membered carbocyclic or heterocyclic ring saturated or unsaturated, said heterocyclic ring

21058PV

containing 1-2 heteroatoms independently chosen from O, C(O), S, SO, SO₂, N, or NR^{2a} and optionally substituted by 1-3 R^a groups;

R⁴ is hydrogen, halo, C₁₋₆ alkyl, and trihaloalkyl;

5

R^a represents C₁₋₆ alkoxy, C₁₋₆ alkyl, CF₃, nitro, amino, cyano, C₁₋₆ alkylamino, or halogen; and

n represents 1-3;

10

or a pharmaceutically acceptable salt, enantiomer, or diastereomer thereof.

In one embodiment of this invention R^{1a} and R¹ independently are hydrogen, tert-butyl, 1,2,2-trichlorovinyl, phenyl, and all other variables are as originally described.

15

In another embodiment of this invention R² is hydrogen or C₁₋₄ alkyl, n is 1 and all other variables are as originally described.

In still another embodiment of this invention

R^{1a} and R¹ independently are hydrogen, tert-butyl, 1,2,2-trichlorovinyl, or phenyl; R² is hydrogen or C₁₋₄ alkyl, n is 1 and all other variables are as originally described.

20

Particular novel compounds of structural formula I which may be employed in the methods, uses and compositions of the present invention, include:

- (1) 2-aminomethyl-5-tert-butyl-3-phenylphenol
- (2) 2-aminomethyl-5-tert-butyl-3-(4-methylphenyl)phenol
- (3) 3,5-di-tert-butyl-2-[(ethylamino)methyl]phenol
- 25 (4) 3,5-di-tert-butyl-2-[1-(ethylamino)ethyl]phenol
- (5) 3,5-di-tert-butyl-2-[(methylamino)methyl]phenol
- (6) 3,5-bis(trichlorovinyl)-2-[(ethylamino)methyl]phenol
- (7) 3,5-di-tert-butyl-2-[(propylamino)methyl]phenol
- (8) 2-[(ethylamino)methyl]-5-(trichlorovinyl)phenol
- 30 (9) 3,5-di-tert-butyl-2-[(butylamino)methyl]phenol
- (10) 3,5-di-tert-butyl-2-[(cyclohexylamino)methyl]phenol
- (11) 3,5-di-tert-butyl-2-[(hexylamino)methyl]phenol
- (12) 3,5-di-tert-butyl-2-[(octylamino)methyl]phenol
- (13) 3,5-di-tert-butyl-2-[(2-hydroxyethylamino)methyl]phenol
- 35 (14) tert-butyl N-(2,4-di-tert-butyl-6-hydroxybenzyl)-beta-alaninate

- (15) 3,5-di-tert-butyl-2-[(2-dimethylaminoethylamino)methyl]phenol
(16) 3,5-di-tert-butyl-2-[(3-phenylpropylamino)methyl]phenol
(17) 3,5-di-tert-butyl-2-[(2-phenylethylamino)methyl]phenol
(18) 3,5-di-tert-butyl-2-[(allylamino)methyl]phenol
5 (19) 5-tert-butyl-2-[(ethylamino)methyl]phenol
(20) 2-[(benzylamino)methyl]-5-tert-butylphenol
(21) 5-tert-butyl-2-[(cyclohexylamino)methyl]phenol
(22) 2-[(cyclohexylamino)methyl]-5-(trichlorovinyl)phenol
(23) 5-tert-butyl-2-{[(2-phenylethyl)amino]methyl}phenol
10 (24) 2-[(benzylamino)methyl]-5-(trichlorovinyl)phenol
(25) 3,5-di-tert-butyl-2-[(decylamino)methyl]phenol
(26) 2-[(propylamino)methyl]-5-(trichlorovinyl)phenol
(27) 5-tert-butyl-2-[(propylamino)methyl]phenol
(28) 5-tert-butyl-2-[(cyclopropylamino)methyl]phenol
15 (29) 5-tert-butyl-2-[(1,2,3,4-tetrahydronaphthalen-1-ylamino)methyl]phenol
(30) 2-[(cyclopropylamino)methyl]-5-(trichlorovinyl)phenol
(31) 2-[(isopropylamino)methyl]-5-(trichlorovinyl)phenol
(32) 2-[(1,2,3,4-tetrahydronaphthalen-1-ylamino)methyl]-5-(trichlorovinyl)phenol
(33) 2-[(2,3-dihydro-1H-inden-1-ylamino)methyl]-5-(trichlorovinyl)phenol
20 (34) 3,5-di-tert-butyl-2-{[(1R)-1-phenylethyl]amino}methyl]phenol
(35) 3,5-di-tert-butyl-2-{[(1-naphthylmethyl)amino]methyl}phenol
(36) 3,5-di-tert-butyl-2-{[(2-naphthylmethyl)amino]methyl}phenol
(37) 2-[(tert-butylamino)methyl]-5-(trichlorovinyl)phenol
(38) 3,5-di-tert-butyl-2-[(1,2,3,4-tetrahydronaphthalen-2-ylamino)methyl]phenol
25 (39) 2-[(cyclohexylamino)methyl]-3-(trichlorovinyl)phenol
(40) 3,5-di-tert-butyl-2-[(2,3-dihydro-1H-inden-2-ylamino)methyl]phenol
(41) 3,5-di-tert-butyl-2-{[(1R)-2,3-dihydro-1H-inden-1-ylamino]methyl}phenol
(42) 3,5-di-tert-butyl-2-{[(1S)-2,3-dihydro-1H-inden-1-ylamino]methyl}phenol
(43) 5-tert-butyl-2-[(2,3-dihydro-1H-inden-2-ylamino)methyl]phenol
30 (44) 5-tert-butyl-2-{[(4-methoxybenzyl)amino]methyl}phenol
(45) 5-tert-butyl-2-[(neopentylamino)methyl]phenol
(46) 5-tert-butyl-2-{[(3,3-dimethylbutyl)amino]methyl}phenol
(47) 5-tert-butyl-2-[2-(cyclohexylamino)ethyl]phenol
(48) 5-tert-butyl-2-[(2,3-dihydro-1H-inden-1-ylamino)methyl]phenol
35 (49) 5-tert-butyl-2-[(isopropylamino)methyl]phenol

21058PV

- (50) 3,5-di-tert-butyl-2-[(decahydronaphthalen-2-ylamino)methyl]phenol
(51) 5-tert-butyl-2-[(isopentylamino)methyl]phenol
(52) 5-tert-butyl-2-[(isobutylamino)methyl]phenol
(53) 5-tert-butyl-2-(piperidin-1-ylmethyl)phenol
5 (54) 3,5-di-tert-butyl-2-[(2-pyridin-2-ylethyl)amino]methyl]phenol
(55) 3,5-di-tert-butyl-2-[(2-pyridin-3-ylethyl)amino]methyl]phenol
(56) 3,5-di-tert-butyl-2-[(2-pyridin-4-ylethyl)amino]methyl]phenol
(57) 3,5-di-tert-butyl-2-[(tetrahydro-2H-pyran-4-ylamino)methyl]phenol
(58) 3,5-di-tert-butyl-2-[(cyclohexylmethyl)amino]methyl]phenol
10 (59) 2-(aminomethyl)-3,5-di-tert-butylphenol
(60) 5-tert-butyl-2-[(3-methoxybenzyl)amino]methyl]phenol
(61) 2-(aminomethyl)-4-bromo-5-tert-butylphenol
(62) ethyl N-(2,4-ditert-butyl-6-hydroxybenzyl)-beta-alaninate
(63) 3-tert-butyl-2-(piperidin-1-ylmethyl)phenol
15 (64) 3-tert-butyl-2-[(cyclohexylamino)methyl]phenol
(65) 2-[2-(cyclohexylamino)ethyl]-5-(trichlorovinyl)phenol
(66) 3-tert-butyl-2-[2-(cyclohexylamino)ethyl]phenol
(67) 3,5-di-tert-butyl-2-[(tetrahydro-2H-pyran-2-ylmethyl)amino]methyl]phenol
(68) 3,5-di-tert-butyl-2-[2-(cyclohexylamino)ethyl]phenol
20 (69) 3,5-di-tert-butyl-2-[(3-furylmethyl)amino]methyl]phenol
(70) 2-[2-(benzylamino)ethyl]-3,5-ditert-butylphenol
and pharmaceutically acceptable salts thereof.

The compounds of the present invention may have asymmetric centers, chiral axes and chiral planes, and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention. (See E.L. Eliel and S.H. Wilen *Stereochemistry of Carbon Compounds* (John Wiley and Sons, New York 1994), in particular pages 1119-1190).

When any variable (e.g. aryl, heterocycle, R^{1a}, R² etc.) occurs more than one time in any constituent, its definition on each occurrence is independent at every other occurrence. Also, combinations of substituents/or variables are permissible only if such combinations result in stable compounds.

The term "alkyl" refers to a monovalent alkane (hydrocarbon) derived radical containing from 1 to 15 carbon atoms unless otherwise defined. It may be

21058PV

straight or branched. Preferred alkyl groups include lower alkyls which have from 1 to 6 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl and t-butyl. When substituted, alkyl groups may be substituted with up to 3 substituent groups, selected from the groups as herein defined, at any available point of attachment. When the 5 alkyl group is said to be substituted with an alkyl group, this is used interchangeably with "branched alkyl group".

Cycloalkyl is a species of alkyl containing from 3 to 15 carbon atoms, without alternating or resonating double bonds between carbon atoms. It may contain from 1 to 4 rings which are fused. Preferred cycloalkyl groups 10 are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. When substituted, cycloalkyl groups may be substituted with up to 3 substituents which are defined herein by the definition of alkyl.

The term "alkoxy" refers to those hydrocarbon groups having an oxygen bridge and being in either a straight or branched configuration and if two or 15 more carbon atoms in length, they may include a double or a triple bond. Exemplary of such alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy allyloxy, propargyloxy, and the like.

20 "Halogen" or "halo" as used herein means fluoro, chloro, bromo and iodo.

The term "alkenyl" refers to a hydrocarbon radical straight, branched or cyclic containing from 2 to 10 carbon atoms and at least one carbon to carbon double bond. Preferred alkenyl groups include ethenyl, propenyl, butenyl and 25 cyclohexenyl. Preferably, alkenyl is C₂-C₆ alkenyl.

Preferably, alkynyl is C₂-C₆ alkynyl.

As used herein, "aryl" is intended to mean any stable monocyclic or bicyclic carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic. Examples of such aryl elements include phenyl, naphthyl, 30 tetrahydronaphthyl, indanyl, biphenyl, phenanthryl, anthryl or acenaphthyl.

The term heterocycle or heterocyclic, as used herein, represents a stable 5- to 7-membered monocyclic or stable 8- to 11-membered bicyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting

of N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. The term heterocycle or heterocyclic includes heteroaryl moieties. Examples of such

5 heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, 1,3-dioxolanyl, furyl, imidazolidinyl, imidazolinyl,

10 imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, 2-oxopiperazinyl, 2-oxopiperdinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl,

15 tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothienyl, and thienyl. An embodiment of the examples of such heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl,

20 benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, 2-oxopiperazinyl, 2-oxopiperdinyl, 2-

25 oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, 2-pyridinonyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothienyl, thienyl and triazolyl.

30 Preferably, heterocycle is selected from 2-azepinonyl, benzimidazolyl, 2-diazapinonyl, imidazolyl, 2-imidazolidinonyl, indolyl, isoquinolinyl, morpholinyl, piperidyl, piperazinyl, pyridyl, pyrrolidinyl, 2-piperidinonyl, 2-pyrimidinonyl, 2-pyrollidinonyl, quinolinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, and thienyl.

As used herein, "heteroaryl" is intended to mean any stable monocyclic
35 or bicyclic carbon ring of up to 7 members in each ring, wherein at least one ring is

aromatic and wherein from one to four carbon atoms are replaced by heteroatoms selected from the group consisting of N, O, and S. Examples of such heterocyclic elements include, but are not limited to, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl,

5 benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, furyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxadiazolyl, pyridyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydroisoquinolinyl, 10 tetrahydroquinolinyl, thiazolyl, thienofuryl, thienothienyl, thienyl and triazolyl.

As used herein, unless otherwise specifically defined, substituted alkyl, substituted cycloalkyl, substituted aroyl, substituted aryl, substituted heteroaroyl, substituted heteroaryl, substituted arylsulfonyl, substituted heteroaryl-sulfonyl and substituted heterocycle include moieties containing from 1 to 3 substituents in addition to the point of attachment to the rest of the compound. Preferably, such substituents are selected from the group which includes but is not limited to F, Cl, Br, CF₃, NH₂, N(C₁-C₆ alkyl)₂, NO₂, CN, (C₁-C₆ alkyl)O-, (aryl)O-, -OH, (C₁-C₆ alkyl)S(O)_m-, (C₁-C₆ alkyl)C(O)NH-, H₂N-C(NH)-, (C₁-C₆ alkyl)C(O)-, (C₁-C₆ alkyl)OC(O)-, (C₁-C₆ alkyl)OC(O)NH-, phenyl, pyridyl, 20 imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, isothiazolyl and C₁-C₂₀ alkyl.

When a functional group is termed "protected", this means that the group is in modified form to preclude undesired side reactions at the protected site. Suitable protecting groups for the compounds of the present invention will be 25 recognized from the present application taking into account the level of skill in the art, and with reference to standard textbooks, such as Greene, T. W. et al. Protective Groups in Organic Synthesis Wiley, New York (1991). Examples of suitable protecting groups are contained throughout the specification.

For use in medicine, the salts of the aminoalkylphenols of formula I 30 will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. When the compound of the present invention is acidic, suitable "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived 35 from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous,

21058PV

lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as arginine, betaine caffeine, choline, N,N¹-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine tripropylamine, tromethamine and the like.

When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric and tartaric acids.

The preparation of the pharmaceutically acceptable salts described above and other typical pharmaceutically acceptable salts is more fully described by Berg *et al.*, "Pharmaceutical Salts," *J. Pharm. Sci.*, 1977:66:1-19.

It will also be noted that the compounds of the present invention are potentially internal salts or zwitterions, since under physiological conditions a deprotonated acidic moiety in the compound, such as a carboxyl group, may be anionic, and this electronic charge might then be balanced off internally against the cationic charge of a protonated or alkylated basic moiety, such as a quaternary nitrogen atom.

The compounds of this invention may be administered to mammals, preferably humans, either alone or, preferably, in combination with pharmaceutically acceptable carriers, excipients or diluents, in a pharmaceutical composition, according to standard pharmaceutical practice. The compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.

21058PV

As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specific amounts, as well as any product which results, directly or indirectly, from combination of the specific ingredients in the specified amounts.

- 5 The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and
10 such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for
15 example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, microcrystalline cellulose, sodium crosscarmellose, corn starch, or alginic acid; binding agents, for example starch, gelatin, polyvinyl-pyrrolidone or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets
20 may be uncoated or they may be coated by known techniques to mask the unpleasant taste of the drug or delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a water soluble taste masking material such as hydroxypropyl-methylcellulose or hydroxypropylcellulose, or a time delay material such as ethyl cellulose, cellulose
25 acetate buryrate may be employed.

- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water soluble carrier such as
30 polyethyleneglycol or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

- Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose,
35 hydroxypropylmethyl-cellulose, sodium alginate, polyvinyl-pyrrolidone, gum

21058PV

tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-
5 oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-
10 propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a
15 thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as butylated hydroxyanisole or alpha-tocopherol.

Dispersible powders and granules suitable for preparation of an
20 aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present. These compositions
25 may be preserved by the addition of an anti-oxidant such as ascorbic acid.

The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring
30 phosphatides, for example soy bean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavoring agents, preservatives and antioxidants.

21058PV

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavoring and coloring agents and antioxidant.

The pharmaceutical compositions may be in the form of a sterile 5 injectable aqueous solutions. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.

The sterile injectable preparation may also be a sterile injectable oil-in-water microemulsion where the active ingredient is dissolved in the oily phase. For example, the active ingredient may be first dissolved in a mixture of soybean oil and 10 lecithin. The oil solution then introduced into a water and glycerol mixture and processed to form a microemulsion.

The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension for intramuscular and subcutaneous administration. This suspension may be formulated according to the known art using 15 those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any 20 bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Compounds of Formula I may also be administered in the form of a suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at 25 ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.

When a compound according to this invention is administered into a 30 human subject, the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, sex and response of the individual patient, as well as the severity of the patient's symptoms.

In one exemplary application, a suitable amount of compound is administered to a mammal undergoing treatment for malaria. Administration occurs 35 in an amount between about 0.1 mg/kg of body weight to about 60 mg/kg of body

21058PV

weight per day, preferably of between 0.5 mg/kg of body weight to about 40 mg/kg of body weight per day.

It is also within the scope of this invention to combine the compounds of this invention with one or more known anti-malarial agents such as Chloroquine,
5 Fansidar, Amodiaquine, Quinine, Halofantrine, Mefloquine, Artemether/Artesunate and Malarone.


Compositions containing the active ingredients of this invention as well as a method for making some of the compounds of formula I are found in US Patent No. 3,794,734, issued February 26, 1974 and incorporated by reference herein.

10 The following examples are illustrative of how to prepare various other novel active ingredients of this invention. However, said examples are merely illustrative and should not be construed as limiting the scope of the invention. All substituents are as defined above unless indicated otherwise.

A preferred synthesis of the novel compounds of this invention is
15 shown in reaction Scheme 1 when it is desired that the nitrogen atom of the amino-substituted sidechain be separated from the phenol ring by one carbon atom ($n = 1$ in general formula I). This process involves a Tcherniac-Einhorn amidoalkylation reaction of the phenol of general formula 1 with an *N*-alkoxymethylamide of general formula 2. The amidoalkylation reaction is generally conducted under acidic reaction conditions which promote the ionization of the alpha-alkoxy group from the amide and produces an acylium ion. Acylium ions are electrophilic species capable of effecting an electrophilic aromatic substitution reaction of the phenol of general formula 1 and the amidoalkylated phenol of general formula 3 is the product. As stated above, the reaction is conducted under acidic conditions. For instance, the
20 reaction of the phenol of general formula 1 and the amide of general formula 2 may be conducted in solution of an organic acid such as acetic acid. The reaction is promoted by addition of a strong mineral acid such as hydrochloric or sulfuric acid. The reaction may be conducted at a variety of temperatures which depend on the relative reactivity of the phenol (1) and the amide (2) that are selected. Typically the reaction
25 is conducted at ambient temperature for periods of a few hours to a few days. Alternatively, the acidic solvent chosen for the reaction can be a stronger acid such as trifluoracetic acid. In this case it is often not necessary to add a mineral acid to promote the amidoalkylation reaction. Here again, while the optimal reaction temperatures and times will depend on the choices of the phenol (1) and the amide (2)

that are selected, frequently these reactions are conducted at ambient temperature for a period of a few hours to a few days.

As shown in reaction Scheme 1, the next step in the synthesis of the novel compounds of general formula I is the hydrolysis of the amide from the intermediate of general formula 3. This hydrolysis reaction is generally conducted in acidic conditions at elevated temperatures. For instance, the amide 3 generally undergoes complete hydrolysis when heated in the presence of a mineral acid such as aqueous hydrochloric or sulfuric acid. The reaction is generally conducted at temperatures between ambient temperature and 100°C for periods of a few hours to one day, and a co-solvent such as an alcohol is usually added to the reaction mixture. As can be seen in reaction Scheme 1, the substituent labeled X is not incorporated into the product of general formula I. However the hydrolysis of the intermediate of general formula 3 may be accelerated when the group X is a halogen atom. Thus it is preferred to utilize the reagent of general formula 2 with X equal to a halogen atom in the first step of the sequence when it is convenient to do so.



Reaction Scheme 2 illustrates one method for introducing additional substituents onto the amine-containing sidechain of compounds of general formula I. In this case a compound of general formula 5 (I; wherein R² are both hydrogen) is subjected to reductive amination with an aldehyde or ketone of general formula 6. The reductive amination may be conducted by one of the many methods for this


21058PV

transformation that are known in organic synthesis. For instance, the amine of general formula 5 and the carbonyl compound of general formula 6 are reacted under conditions which promote the formation of an imine, which is then reduced to afford the product of general formula 7 using a reducing agent such as sodium

5 cyanoborohydride or sodium triacetoxyborohydride. A variety of solvents may be employed for this reaction. For instance, when sodium cyanoborohydride is used as the reducing agent, methanol is a frequently used as solvent. Alternatively, when sodium triacetoxyborohydride is the chosen reducing agent, then aprotic solvents such as dichloromethane, 1,2-dichloroethane or toluene are generally used. It is

10 occasionally advantageous to conduct the reaction in two stages. Often, the amine of general formula 5 and the carbonyl compound of general formula 6 are initially induced to form an imine intermediate. The progress of this step may be monitored spectroscopically or chromatographically (e.g. by TLC). Upon completion of imine formation, the reducing agent is then added and the reduction of the imine proceeds to

15 produce the product of general formula 7.

Scheme 2

20


Reaction Scheme 3 illustrates an alternative method for introducing additional substituents onto the amine-containing sidechain of compounds of general formula I. In this case, an amine of general formula 8 (I; wherein R², R³ and R^{3a} are all hydrogen) is first oxidized using a modification of the Sommelet reaction to afford

25 a substituted salicylaldehyde derivative of general formula 9. The salicylaldehyde 9 is then subjected to reductive amination with a primary or secondary amine of general formula 10 to afford compounds of general formula 11 (I; where R³ and R^{3a} equal hydrogen). The oxidation step is accomplished by heating the amine of general formula 8 with hexamethylenetetramine in an aqueous acidic solvent such as a

21058PV

mixture of water and acetic acid. The reaction is conducted at elevated temperatures, for instance between 100-150°C for a period of several hours. The reductive amination of the aldehyde of general formula 9 with an amine of general formula 10 is conducted in a manner similar to the reductive amination described for compounds of 5 general formula 5 and 6 in reaction Scheme 2. Typically compounds 9 and 10 are reacted together under conditions that promote formation of an imine and then a reducing agent such as sodium triacetoxyborohydride is added to effect reduction of the imine and formation of the compound of general formula 11. Finally, it is recognized that alternative synthetic methodologies known in organic synthesis may 10 offer advantages for the preparation of the intermediate salicylaldehyde of general formula 9. For instance, depending upon the selection of the other substituents in the final product of general formula I, it may be advantageous to prepare the aldehyde of general formula 9 from a phenol of general formula 1 using a Reimer-Tiemann reaction or a Duff reaction.

15

Scheme 3

20


Reaction Scheme 4 illustrates two additional synthetic methods for the modification of the amine-containing sidechains of the novel compounds of the present invention. In the first reaction, an amine of general formula 5 is reacted with an alkylating agent of formula 12 containing the R² substituent. In compounds of general formula 12, the group X is a leaving group such as a halogen, mesylate, 25 triflate or the like. The reaction is conducted in a suitable organic solvent such as an

21058PV

alcohol, a halocarbon solvent etc., and the stoichiometry of the reagent **12** is controlled to afford either the mono- or bis-alkylated derivatives **13a** or **13b** respectively. The reaction at the bottom of reaction Scheme 4 illustrates a two-step conversion of the compound of general formula **5** to a compound of general formula **15**.

5 In the first step, the amine of general formula **5** is acylated with an acylating agent of general formula **14**. The acylating agent **14** may be either a carboxylic acid halide or anhydride, a mixed-anhydride, or any activated ester typically used to effect the acylation reaction of an amine. In the second step of this sequence, the amide produced in the acylation step is reduced with a reagent capable of reducing amides to

10 amines. For instance, reduction of the intermediate amide with lithium aluminum hydride or diborane in solvents such as THF produces the amine derivative of general formula **15**.

Scheme 4

15

The following examples are illustrative of how to prepare various other novel active ingredients of this invention. However, said examples are merely illustrative and should not be construed as limiting the scope of the invention.

20 General Procedures.

The HPLC/MS analyses were preformed using a Micromass ZMD mass spectrometer coupled to an Agilent 1100 Series HPLC utilizing a YMC ODS-A 4.6 x 50 mm column eluting at 2.5 mL/min with a solvent gradient of 10 to 95% B:A over 4.5 min, then 0.5 min at 95% B: solvent A = 0.06% TFA in water; solvent B = 25 0.05% TFA in acetonitrile.

21058PV

Proton NMR spectra were obtained with a 400MHz Varian Spectrometer in CDCl_3 or CD_3OD and chemical shifts are reported as δ using the deuterium of the solvent as standard and coupling constants are reported in hertz.

5

EXAMPLE 1

2-Aminomethyl-5-*tert*-butylphenol hydrochloride

Step A: *N*-(4-*tert*-butyl-2-hydroxybenzyl)-2-chloroacetamide

A finely powdered mixture of 15 g (0.10 mol) of 3-*tert*-butylphenol and 12.4 g (0.10 mol) of *N*-hydroxymethyl-2-chloroacetamide was added in portions to a vigorously stirred solution of 90 mL acetic acid and 10 mL (98%) sulfuric acid at 0°C. The reaction mixture was allowed to warm to room temperature over several hours, and stirring was maintained for a total of 20 hours. The reaction mixture was poured into ice-water, neutralized with saturated aqueous NaHCO_3 solution and extracted into CH_2Cl_2 . The organic extracts were combined, washed with brine, dried (Na_2SO_4), filtered and evaporated. The residue was purified on a silica gel flash chromatography column eluted with 10-30% EtOAc in hexane. Evaporation of the purified fractions and drying *in vacuo* afforded the title compound.

Step B: 2-Aminomethyl-5-*tert*-butylphenol hydrochloride

To a solution of 50 mL ethanol and 15 mL conc. hydrochloric acid was added 3.58 g (0.014 mol) of the product of Step A and the reaction mixture was stirred and heated to 85°C using an external oil bath for 3 h. The reaction mixture was then cooled to room temperature and evaporated *in vacuo*. Excess water was removed from the product mixture by azeotropic distillation of added portions of toluene on a rotary evaporator. The residue was triturated with ether and dried overnight *in vacuo* to afford the title compound as a white crystalline solid.

HPLC/MS: 162.7 [(M+1)-NH₃]; R_f = 1.55 min.

EXAMPLE 2

5-*tert*-Butyl-2-[(ethylamino)methyl]phenol

To a solution of 0.10 g (0.39 mmol) of the product of Step A in Example 1 in 2 mL of anhydrous THF was added 1.95 mL (1.95 mmol) of a 1.0 M solution of lithium aluminum hydride in THF and the reaction mixture was stirred at room temperature for 30 min. The reaction mixture was cooled to room temperature and cautiously quenched with 10% aqueous citric acid. The resulting emulsion was

repeatedly extracted with EtOAc and CH₂Cl₂. The combined organic layers were dried (Na₂SO₄), filtered and evaporated. The residue was purified on preparative thin-layer chromatography plates eluted with CH₂Cl₂-MeOH-NH₄OH (95:4:1) to afford the title compound. HPLC/MS: 208.1 (M+1); R_f = 1.8 min.

5

EXAMPLE 3

2-[*(Benzylamino)methyl]-5-*tert*-butylphenol*

To a mixture of 0.216 g (1.0 mmol) of the product of Example 1 and 0.108 g (0.1 mmol) of benzaldehyde suspended in 5 mL of 1,2-dichloroethane was added 0.5 mL acetic acid and 1 g of finely powdered 4Å molecular sieves. The reaction mixture was stirred under a nitrogen atmosphere at room temperature overnight, then 1.12 g (5 mmol) of sodium triacetoxyborohydride was added. The reaction was then stirred an addition day at room temperature , then diluted with CH₂Cl₂ and MeOH. The mixture was filtered through a pad of Celite filter aid eluted with CH₂Cl₂, and the filtrate was washed with saturated aq. NaHCO₃. The organic layer was the separated, dried (Na₂SO₄), filtered and evaporated *in vacuo*. The residue was purified on a flash chromatography column eluted with CH₂Cl₂-MeOH-NH₄OH (97:2:1) to afford the title compound. HPLC/MS: 270.1 (M+1); R_t = 2.2 min.

20

EXAMPLES 4-7

Using the procedure described in Example 3 above, reductive amination of the product of Example 1 with the appropriate aldehyde or ketone afforded the following compounds:

25

Ex. #	Compound	HPLC-MS <i>m/z</i> (M+1); R _t (min)
4	5- <i>tert</i> -Butyl-2-[(cyclohexylamino)methyl]phenol	262.1; 2.2
5	5- <i>tert</i> -Butyl-2-{[(2-phenylethyl)amino]methyl}phenol	284.0; 2.5
6	5- <i>tert</i> -Butyl-2-[(2,3-dihydro-1H-inden-2-ylamino)methyl]phenol	296.1; 2.5
7	5- <i>tert</i> -Butyl-2-{[(3-methoxybenzyl)amino]methyl}phenol	300.1; 2.4

21058PV

EXAMPLE 8

5-tert-Butyl-2-[*(propylamino)methyl*]phenolStep A: 4-tert-Butyl-2-hydroxybenzaldehyde

- To a solution of 1.5 g (6.9 mmol) of the product of Example 1 in 15 mL of HOAc-H₂O (11:3) was added 1.17 g (8.3 mmol) of hexamethylenetetramine dissolved in 3 mL water. The reaction mixture was magnetically stirred and heated at 130°C for 3 h at which point 13.5 mL of a 2:1 solution of conc. hydrochloric acid and water was added. The reaction mixture was heated for an additional 10 min at 130°C, then cooled to room temperature and the acetic acid was removed on a rotary evaporator. The residue was partitioned between EtOAc and water, then extracted. The organic layers were combined and dried (Na₂SO₄). The filtrate was passed through a layer of Celite filter aid mixed with silica gel to remove polar impurities, then evaporated. The residual oil was dried *in vacuo* and subsequently used in the next step without further purification.
- Step B: 5-tert-Butyl-2-[*(propylamino)methyl*]phenol
- To a mixture of 0.178 g (0.1 mmol) of the product of Step A and 0.206 g (3.5 mmol) of *n*-propylamine dissolved in 10 mL of CH₂Cl₂ was added 0.5 g of finely powdered 4Å molecular sieves. The reaction mixture was stirred under a nitrogen atmosphere at room temperature overnight, then 0.53 g (2.5 mmol) of sodium triacetoxyborohydride was added. The reaction was then stirred an addition 8 h at room temperature, then diluted with CH₂Cl₂ and MeOH. The mixture was filtered through a pad of Celite filter aid eluted with CH₂Cl₂, and the filtrate was washed with saturated aq. NaHCO₃. The organic layer was the separated, dried (Na₂SO₄), filtered and evaporated *in vacuo*. The residue was purified on a flash chromatography column eluted with CH₂Cl₂-MeOH-NH₄OH (95:4:1) to afford the title compound. HPLC/MS: 222.0 (M+1); R_t = 1.9 min.

EXAMPLE 9-18

- Using the procedure described in Step B of Example 8 above, reductive amination of the aldehyde produced in Step A from Example 8 with the appropriate amine afforded the following compounds:

Ex. #	Compound	HPLC-MS <i>m/z</i> (M+1); <i>R</i> _t (min)
9	5- <i>tert</i> -Butyl-2-[(cyclopropylamino)methyl]phenol	220.1; 1.8
10	5- <i>tert</i> -Butyl-2-[(1,2,3,4-tetrahydronaphthalen-1-ylamino)methyl]phenol	310.1; 2.6
11	5- <i>tert</i> -Butyl-2-[(4-methoxybenzyl)amino]methyl]phenol	300.1; 2.5
12	5- <i>tert</i> -Butyl-2-[(neopentylamino)methyl]phenol	250.2; 2.2
13	5- <i>tert</i> -Butyl-2-[(3,3-dimethylbutyl)amino]methyl]phenol	264.1; 2.6
14	5- <i>tert</i> -Butyl-2-[(2,3-dihydro-1H-inden-1-ylamino)methyl]phenol	296.1; 2.5
15	5- <i>tert</i> -Butyl-2-[(isopropylamino)methyl]phenol	222.1; 1.9
16	5- <i>tert</i> -Butyl-2-[(isopentylamino)methyl]phenol	250.1; 2.4
17	5- <i>tert</i> -Butyl-2-[(isobutylamino)methyl]phenol	236.1; 2.2
18	5- <i>tert</i> -Butyl-2-(piperidin-1-ylmethyl)phenol	248.2; 2.1

EXAMPLE 19

2-(aminomethyl)-3,5-di-*tert*-butylphenol hydrochlorideStep A: 2-Chloro-N-(2,4-di-*tert*-butyl-6-hydroxybenzyl)acetamide

5 A finely powdered mixture of 5.2 g (25 mmol) of 3,5-di-*tert*-butylphenol and 3.15 g (25 mmol) of *N*-hydroxymethyl-2-chloroacetamide was added in portions to a vigorously stirred solution of 22.5 mL acetic acid and 2.5 mL (98%) sulfuric acid at 0-10°C. The reaction mixture was allowed to warm to room temperature over several hours, and stirring was maintained for a total of 16 hours.

10 The reaction mixture was poured into ice-water, neutralized with saturated aqueous NaHCO₃ solution and extracted into CH₂Cl₂. The organic extracts were combined, washed with brine, dried (Na₂SO₄), filtered and evaporated. The residue was purified on a silica gel flash chromatography column eluted with 15-30-50% EtOAc in hexane. Evaporation of the purified fractions and drying *in vacuo* afforded the title compound.

15 Step B: 2-(aminomethyl)-3,5-di-*tert*-butylphenol hydrochloride
To a solution of 50 mL ethanol and 15 mL conc. hydrochloric acid was added 4.35 g (0.014 mol) of the product of Step A and the reaction mixture was stirred and heated to 85°C using an external oil bath for 3 h. The reaction mixture was then cooled to room temperature and evaporated *in vacuo*. Excess water was removed from the product mixture by azeotropic distillation of added portions of

toluene on a rotary evaporator. The residue was triturated with ether and dried overnight *in vacuo* to afford the title compound as a white crystalline solid.
HPLC/MS: 218.9 [(M+1)-NH₃]; R_t = 2.3 min.

5

EXAMPLE 20

3,5-Di-*tert*-butyl-2-[(ethylamino)methyl]phenol

To 0.311 g (1.00 mmol) of the product of Step A in Example 19 dissolved in 10 mL of THF was added 0.2 g (5.27 mmol) lithium aluminum hydride in portions. The resulting mixture was stirred at room temperature overnight at which point 3 mL of EtOAc was slowly added to decompose the remaining hydride reagent. After stirring an additional 30 min the reaction mixture was quenched by cautious addition of 10% aq. NH₄Cl. The resulting mixture was filtered through Celite filter aid, then concentrated *in vacuo*. The residue was purified on a silica gel flash chromatography column eluted with CH₂Cl₂-MeOH-NH₄OH (97:3:0.3) to afford the title compound. HPLC/MS: 264.2 (M+1); R_t = 2.69 min.

10

15

EXAMPLE 21

3,5-Di-*tert*-butyl-2-[(butylamino)methyl]phenol

To a mixture of 0.47 g () of the product of Example 19 and 0.15 g () of n-butyraldehyde in 10 mL of 1,2-dichloroethane was added 25 drops of acetic acid and 3 g of finely powdered 4 Å molecular sieves. The mixture was stirred 5 h at room temperature at which point 1 g of sodium triacetoxyborohydride was added. The reaction mixture was stirred overnight at room temperature, then diluted with 10 mL CH₂Cl₂ and filtered through a layer of Celite filter aid. The filtrate was washed with excess saturated aq. NaHCO₃, the aqueous layer was extracted with CH₂Cl₂, then the organic layers were combined, dried (Na₂SO₄), filtered and evaporated. The residue was purified on a silica gel flash chromatography column eluted with 0-10% EtOAc in CH₂Cl₂. Evaporation of the purified fractions and drying *in vacuo* afforded the title compound. HPLC/MS: 292.2 (M+1); R_t = 2.8 min.

20

25

30

EXAMPLES 22-34

Using the procedure described in Example 21 above, reductive amination of the product of Example 19 with the appropriate aldehyde or ketone afforded the following compounds:

21058PV

Ex. #	Compound	HPLC-MS <i>m/z</i> (M+1); R _t (min)
22	3,5-Di- <i>tert</i> -butyl-2-[(cyclohexylamino)methyl]phenol	318.1; 2.9
23	3,5-Di- <i>tert</i> -butyl-2-[(hexylamino)methyl]phenol	320.2; 3.2
24	3,5-Di- <i>tert</i> -butyl-2-[(octylamino)methyl]phenol	348.2; 3.6
25	3,5-Di- <i>tert</i> -butyl-2-[(3-phenylpropylamino)methyl]phenol	354.1; 3.1
26	3,5-Di- <i>tert</i> -butyl-2-[(2-phenylethylamino)methyl]phenol	340.1; 3.0
27	3,5-Di- <i>tert</i> -butyl-2-[(decylamino)methyl]phenol	376.2; 4.1
28	3,5-Di- <i>tert</i> -butyl-2-{{(1-naphthylmethyl)amino}methyl}phenol	376.1; 3.4
29	3,5-Di- <i>tert</i> -butyl-2-{{(2-naphthylmethyl)amino}methyl}phenol	376.1; 3.5
30	3,5-Di- <i>tert</i> -butyl-2-[(1,2,3,4-tetrahydronaphthalen-2-ylamino)methyl]phenol	366.3; 3.2
31	3,5-Di- <i>tert</i> -butyl-2-[(decahydronaphthalen-2-ylamino)methyl]phenol	372.3; 3.6
32	3,5-Di- <i>tert</i> -butyl-2-[(tetrahydro-2H-pyran-4-ylamino)methyl]phenol	320.2; 2.6
33	3,5-Di- <i>tert</i> -butyl-2-{{(cyclohexylmethyl)amino}methyl}phenol	332.2; 3.3
34	3,5-Di- <i>tert</i> -butyl-2-{{(3-furylmethyl)amino}methyl}phenol	316.1; 2.8

EXAMPLE 35

3,5-Di-*tert*-butyl-2-[(methylamino)methyl]phenol

- 5 Step A: 2,4-Di-*tert*-butyl-6-hydroxybenzaldehyde
- To a solution of 1.25 g (4.60 mmol) of the product of Example 19 (hydrochloride salt) in 10 mL of acetic acid-water (11:3) was added 0.75 g () of hexamethylenetetramine. The mixture was refluxed for 3 h then treated with 6 mL of water and 3 mL of conc. hydrochloric acid. Heating was continued for 10 min at
- 10 which point the reaction mixture was cooled and concentrated in vacuo to remove the acetic acid. The residue was partitioned between EtOAc and water, and the aqueous layer was separated and extracted. The combined organic layers were washed with brine, dried (Na₂SO₄), filtered and evaporated. The product was purified on a silica gel flash chromatography column eluted with 5% EtOAc-hexane. Evaporation of the
- 15 purified fractions afforded the title compound.

21058PV

Step B: 3,5-Di-*tert*-butyl-2-[*(methylamino)methyl*]phenol

- A mixture of 0.234 g (1.00 mmol) of the product of Step A, 3 mL of 2 N methylamine in THF, and 0.5 mL acetic acid dissolved in 4.0 mL 1,2-dichloroethane was stirred at room temperature for 5 h. Sodium 5 triacetoxyborohydride (0.422 g; 2.0 mmol) and 10 mL of 1,2-dichloroethane was then added and the resulting mixture was stirred overnight at room temperature. The reaction mixture was then treated with excess saturated aq. NaHCO₃. The aqueous layer was separated and extracted with CH₂Cl₂, the organic layers were combined, dried (Na₂SO₄), filtered, and evaporated. The residue was purified on a silica gel 10 flash chromatography column eluted with CH₂Cl₂-MeOH-NH₄OH (95:5:0.5). Evaporation of the purified fractions and drying *in vacuo* afforded the title compound. HPLC/MS: 250.2 (M+1); R_t = 2.5 min.

EXAMPLES 36-47

- 15 Using the procedure described in Step B of Example 35, reductive amination of the aldehyde produced in Step A of Example 35 with the appropriate amine afforded the following compounds:

Ex. #	Compound	HPLC-MS m/z; R _t (min)
36	3,5-Di- <i>tert</i> -butyl-2-[<i>(2-hydroxyethylamino)methyl</i>]phenol	280.2; 2.4
37	<i>tert</i> -Butyl N-(2,4-Di- <i>tert</i> -butyl-6-hydroxybenzyl)-beta-alaninate	364.1; 3.0
38	3,5-Di- <i>tert</i> -butyl-2-[<i>(2-dimethylaminoethylamino)methyl</i>]phenol	307.1; 2.0
39	3,5-Di- <i>tert</i> -butyl-2-{[(1R)-1-phenylethyl]amino}methyl]phenol	340.1; 3.1
40	3,5-Di- <i>tert</i> -butyl-2-[<i>(2,3-dihydro-1H-inden-2-ylamino)methyl</i>]phenol	352.4; 3.1
41	3,5-Di- <i>tert</i> -butyl-2-{[(1R)-2,3-dihydro-1H-inden-1-ylamino]methyl}phenol	352.2; 3.2
42	3,5-Di- <i>tert</i> -butyl-2-{[(1S)-2,3-dihydro-1H-inden-1-ylamino]methyl}phenol	352.2; 3.1
43	3,5-Di- <i>tert</i> -butyl-2-{[(2-pyridin-2-ylethyl)amino]methyl}phenol	341.2; 2.6
44	3,5-Di- <i>tert</i> -butyl-2-{[(2-pyridin-3-ylethyl)amino]methyl}phenol	341.2; 2.3
45	3,5-Di- <i>tert</i> -butyl-2-{[(2-pyridin-4-ylethyl)amino]methyl}phenol	341.2; 2.2
46	Ethyl N-(2,4-di- <i>tert</i> -butyl-6-hydroxybenzyl)-beta-alaninate	336.2; 2.9

21058PV

47	<u>3,5-Di-<i>tert</i>-butyl-2-{[(tetrahydro-2H-pyran-2-ylmethyl)amino]methyl}phenol</u>	334.2; 3.0
----	-----------------------------------------------------------------------------------------	------------

EXAMPLE 482-(1-Aminoethyl)-3,5-di-*tert*-butylphenolStep A: N-[1-(2,4-di-*tert*-butyl-6-hydroxyphenyl)ethyl]acetamide

5 To a solution of 2.06 g (10.0 mmol) of 3,5-di-*tert*-butylphenol in 10 mL of trifluoroacetic acid was added 1.6 g (11.0 mmol) of *N*-(1-isopropoxyethyl)acetamide and the resulting mixture was stirred overnight at room temperature. The reaction mixture was concentrated *in vacuo*, and the residue was partitioned between EtOAc and saturated aq. NaHCO₃. The aqueous layers were
 10 separated and then extracted with EtOAc. The organic layers were combined, dried (Na₂SO₄), filtered and evaporated *in vacuo*. The product was purified on a silica gel flash chromatography column eluted with 0-25% EtOAc in CH₂Cl₂. Evaporation of the purified fraction and drying *in vacuo* afforded the title compound. HPLC/MS: 292.1 (M+1); R_t = 3.3 min.

15 Step B: 2-(1-Aminoethyl)-3,5-di-*tert*-butylphenol

Using the hydrolysis procedure described in Step B of Example 19 the product of Step was converted to the title compound. HPLC/MS: 233.2 [(M+1)-NH₃]; R_t = 2.67 min.

EXAMPLE 493,5-Di-*tert*-butyl-2-[1-(ethylamino)ethyl]phenol

Using the procedure described in Example 20, the product of Step A from Example 48 was reduced with lithium aluminum hydride to afford the title compound.

25 HPLC/MS: 278.4 (M+1); R_t = 2.91 min.**EXAMPLE 50**3,5-Di-*tert*-butyl-2-[(propylamino)methyl]phenolStep A: 3,5-Di-*tert*-butyl-2-[(propionylamino)methyl]phenyl propionate

30 To 0.5 g (2.12 mmol) of the product of Example 19 in 20 mL of CH₂Cl₂ was added 2 mL triethylamine and 0.5 g (5.4 mmol) of propionyl chloride. The reaction mixture was stirred at room temperature for 1 h then quenched with

21058PV

saturated aq. NaHCO₃. The aqueous layer was extracted with CH₂Cl₂, the organic layers were combined, dried (Na₂SO₄), filtered and evaporated *in vacuo*. The crude title compound was used directly in the next step without further purification.

HPLC/MS: 275.2 [(M+1)-NHCOC₂H₅)]; R_t = 3.85 min.

5 Step B: 3,5-Di-tert-butyl-2-[propylamino)methyl]phenol

Using the procedure described in Example 20, the product of Step A from was reduced with lithium aluminum hydride to afford the title compound.

HPLC/MS: 278.1 (M+1); R_t = 2.7 min.

10

EXAMPLE 51

3,5-Di-tert-butyl-2-[allylamino)methyl]phenol

To 0.705 g (2.99 mmol) of the product of Example 19 in 15 mL of CH₂Cl₂ was added 1 g of solid NaHCO₃ followed by 0.525 g (3.12 mmol) of allyl iodide. The reaction mixture was stirred overnight at room temperature, then filtered and evaporated *in vacuo*. The residue was purified on a silica gel flash chromatography column eluted with 0-1% MeOH in CH₂Cl₂. Evaporation of the purified fractions and drying *in vacuo* afforded the title compound. HPLC/MS: 276.1 (M+1); R_t = 2.7 min.

20

EXAMPLE 53

2-(Aminomethyl)-5-(trichlorovinyl)phenol

Step A: 2,2,2-Trichloro-1-(3-methoxyphenyl)ethanol

To a solution of 1.8 mL (22.5 mmol) of chloroform in 10 mL DMF was added 1.4 g (10 mmol) of 3-methoxybenzaldehyde. The reaction mixture was chilled to 0°C and a solution of 400 mg (7 mmol) of potassium hydroxide in 1.8 mL of methanol was added. The reaction mixture was stirred for 3 h at 0°C, then was quenched by addition of 1 mL of 1 N hydrochloric acid. The reaction mixture was adjusted to pH = 7, then extracted with EtOAc. The organic layers were washed with brine, dried (Na₂SO₄), filtered and evaporated. The product was used in the next step without further purification.

30

Step B: 1-Methoxy-3-(1,2,2,2-tetrachloroethyl)benzene

To a suspension of 2.4 g (11.0 mmol) of phosphorous pentachloride in 7.0 mL of CH₂Cl₂ was added a solution of 2.28 g (9.0 mmol) of the product of Step A in 5.0 mL of CH₂Cl₂. The reaction mixture became homogenous while it was stirred

21058PV

at room temperature for 3 h. The reaction mixture was then cooled to 0°C with an external ice-water bath and ice and water was added. The reaction mixture was allowed to warm to room temperature while stirring for 1 h, and was then extracted with CH₂Cl₂. The organic layers were combined, dried (Na₂SO₄), filtered and 5 evaporated. The residue was purified on a silica gel flash chromatography column eluted with 5-20% EtOAc-hexane. Evaporation of the purified fractions afforded the title compound as a colorless oil.

Step C: 1-Methoxy-3-(trichlorovinyl)benzene
To a magnetically stirred solution of 0.228 g (5.7 mmol) of sodium 10 hydroxide in 2.0 mL methanol was slowly added a solution of 1.2 g (4.4 mmol) of the product of Step B in 1.0 mL methanol. A white precipitate was deposited and the reaction mixture was stirred for an additional 3 h. At this point the reaction mixture was evaporated *in vacuo* and the residue was purified on a silica gel flash chromatography column eluted with hexane. Evaporation of the purified fractions 15 afforded the title compound.

Step D: 3-(Trichlorovinyl)phenol
A solution of 3.0 g (12.0 mmol) of boron tribromide in 10 mL of CH₂Cl₂ was magnetically stirred at 0°C with an external ice-water bath, while a 20 solution of 2.38 g (10.0 mmol) of the product of Step C in 20 mL CH₂Cl₂ was slowly added over a period of 1 h. At this point the reaction mixture was allowed to slowly warm to room temperature and stirring was continued for an additional 5 h. The reaction was again cooled to 0°C and quenched by addition of 40 mL water. The organic layer was separated and then washed with 2 N NaOH. The aqueous extracts were acidified with 1 N HCl and extracted with ether. The organic extracts were 25 combined, washed with brine, dried (MgSO₄), filtered and evaporated *in vacuo* to afford the title compound which was used directly in the next step without further purification.

Step E: 2-Chloro-N-[2-hydroxy-4-(trichlorovinyl)benzyl]acetamide
A mixture of 2.02 g (9.0 mmol) of the product of Step D and 1.10 g 30 (9.0 mmol) of *N*-hydroxymethyl-2-chloroacetamide was added in portions to a vigorously stirred solution of 9.0 mL acetic acid and 1.0 mL (98%) sulfuric acid at 0-10°C. The reaction mixture was allowed to warm to room temperature over several hours, and stirring was maintained for a total of 2 days. The reaction mixture was poured into ice-water, neutralized with saturated aqueous NaHCO₃ solution and

21058PV

extracted into CH_2Cl_2 . The organic extracts were combined, washed with brine, dried (Na_2SO_4), filtered and evaporated. The residue was purified on a silica gel flash chromatography column eluted with 10-20-30% EtOAc in hexane. Evaporation of the purified fractions and drying *in vacuo* afforded the title compound.

5 Step F: 2-(Aminomethyl)-5-(trichlorovinyl)phenol

To a solution of 5 mL ethanol and 1.5 mL conc. hydrochloric acid was added 0.818 g (2.5 mmol) of the product of Step E and the reaction mixture was stirred and heated to 85°C using an external oil bath overnight. The reaction mixture was then cooled to room temperature and evaporated *in vacuo*. The residue was 10 triturated with ether and dried overnight *in vacuo* to afford the title compound as a white crystalline solid. HPLC/MS: 236.9 [(M+1)- NH_3]; R_t = 2.0 min.

EXAMPLE 54

2-[(Ethylamino)methyl]-5-(trichlorovinyl)phenol

15 Using the procedure described in Example 2, the product of Step E in Example 53 was reduced with lithium aluminum hydride to afford the title compound.

EXAMPLES 55 and 56

Using the procedure described in Example 3, the product of Step F in

20 Example 53 was subjected to reductive amination with cyclohexanone and benzaldehyde to afford the following compounds respectively:

2-[(cyclohexylamino)methyl]-5-(trichlorovinyl)phenol which had HPLC/MS: 334.0

(M+1); R_t = 2.5 min.

2-[(benzylamino)methyl]-5-(trichlorovinyl)phenol which had HPLC/MS: 342.0

25 (M+1); 2.5 R_t = min.

EXAMPLE 57

2-[(propylamino)methyl]-5-(trichlorovinyl)phenol

Step A: 2-hydroxy-4-(trichlorovinyl)benzaldehyde

30 To a solution of 0.375 g (1.3 mmol) of the product of Step F in Example 53 in 3.0 mL of $\text{HOAc-H}_2\text{O}$ (11:3) was added 1.17 g (8.3 mmol) of hexamethylenetetramine dissolved in 1.0 mL water. The reaction mixture was magnetically stirred and heated at 130°C for 3 h at which point 3 mL of a 2:1 solution of water and conc. hydrochloric acid was added. The reaction mixture was heated for

21058PV

an additional 10 min at 130°C, then cooled to room temperature and the acetic acid was removed on a rotary evaporator. The residue was partitioned between EtOAc and water, then extracted. The organic layers were combined and dried (Na_2SO_4). The filtrate was passed through a layer of Celite filter-aid, then evaporated. The residual oil was dried *in vacuo* and subsequently used in the next step without further purification.

5 Step B: 2-[(propylamino)methyl]-5-(trichlorovinyl)phenol
 To a mixture of 0.211 g (0.84 mmol) of the product of Step A and
 10 0.177 g (2.94 mmol) of *n*-propylamine dissolved in 8 mL of CH_2Cl_2 was added 0.5 g
 of finely powdered 4Å molecular sieves. The reaction mixture was stirred under a
 nitrogen atmosphere at room temperature overnight, then 0.445 g (2.1 mmol) of
 15 sodium triacetoxyborohydride was added. The reaction was then stirred an addition 8
 h at room temperature, then diluted with CH_2Cl_2 and MeOH. The mixture was
 filtered through a pad of Celite filter aid eluted with CH_2Cl_2 , and the filtrate was
 15 washed with saturated aq. NaHCO_3 . The organic layer was the separated, dried
 (Na_2SO_4), filtered and evaporated *in vacuo*. The residue was purified on a silica gel
 flash chromatography column eluted first with CH_2Cl_2 -MeOH-NH₄OH (96:3:1)
 followed by CH_2Cl_2 -MeOH-NH₄OH (94:5:1). Evaporation of the purified fractions
 and drying *in vacuo* afforded the title compound. HPLC/MS: 293.8 (M+1); R_t = 2.2
 20 min.

EXAMPLES 58-63

Using the procedure described in Step B of Example 8 above, reductive amination of the aldehyde produced in Step A from Example 57 with the appropriate amine
 25 afforded the following compounds:

Ex. #	Compound	HPLC-MS <i>m/z</i> (M+1); R_t (min)
58	2-[(cyclopropylamino)methyl]-5-(trichlorovinyl)phenol	291.9; 2.1
59	2-[(isopropylamino)methyl]-5-(trichlorovinyl)phenol	293.8; 2.1
60	2-[(1,2,3,4-tetrahydronaphthalen-1-ylamino)methyl]-5-(trichlorovinyl)phenol	382.0; 2.7

21058PV

61	2-[(2,3-dihydro-1H-inden-1-ylamino)methyl]-5-(trichlorovinyl)phenol	368.0; 2.6
62	2-[(<i>tert</i> -butylamino)methyl]-5-(trichlorovinyl)phenol	307.9; 2.2

EXAMPLE 63

2-(Aminomethyl)-3,5-bis(trichlorovinyl)phenolStep A: 1-Methoxy-3,5-bis(1-hydroxy-2,2,2-trichloroethyl)benzene

5 To a solution of 0.60 g (5 mmol) of chloroform in 2 mL DMF was added 0.164 g (1.0 mmol) of 5-methoxy-1,3-diformylbenzene (Provent, C; Chautemps, P.; Gellon, G.; Pierre, J.-L. *Tetrahedron Lett.* 1996, 37, 1393-96). The reaction mixture was chilled to 0°C and a solution of 39.5 mg (0.7 mmol) of potassium hydroxide in 0.2 mL of methanol was added. The reaction mixture was stirred for 20 min at 0°C, then was quenched by addition of 1 mL of 1 N hydrochloric acid. The reaction mixture was adjusted to pH = 7, then extracted with EtOAc. The organic layers were washed with brine, dried (Na_2SO_4), filtered and evaporated. The product was used in the next step without further purification.

Step B: 1-Methoxy-3,5-bis(1,2,2,2-tetrachloroethyl)benzene

15 To a suspension of 0.376 g (1.8 mmol) of phosphorous pentachloride in 0.5 mL of CH_2Cl_2 was added a solution of 0.301 g (0.75 mmol) of the product of Step A in 0.4 mL of CH_2Cl_2 . The reaction mixture became homogenous while it was stirred at room temperature for 30 min. The reaction mixture was then quenched by addition of ice and water, then allowed to warm to room temperature while stirring for 20 min. The reaction mixture was extracted with CH_2Cl_2 , the organic layers were combined, dried (Na_2SO_4), filtered and evaporated. The residue was purified on a silica gel flash chromatography column eluted with 0-20% EtOAc-hexane. Evaporation of the purified fractions afforded the title compound.

Step C: 1-Methoxy-3,5-bis(trichlorovinyl)benzene

25 To a magnetically stirred solution of 30 mg (0.73 mmol) of sodium hydroxide in 0.2 mL methanol was slowly added a solution of 0.122 g (0.28 mmol) of the product of Step B in 0.1 mL methanol. A white precipitate was deposited and the reaction mixture was then stirred overnight. The reaction mixture was then evaporated *in vacuo* and the residue was purified on a silica gel flash chromatography column eluted with hexane. Evaporation of the purified fractions afforded the title compound.

21058PV

Step D: 3,5-Bis(trichlorovinyl)phenol

A solution of 0.153 g (0.6 mmol) of boron tribromide in 0.5 mL of CH₂Cl₂ was magnetically stirred at 0°C with an external ice-water bath, while a solution of 0.093 g (0.25 mmol) of the product of Step C in 0.5 mL CH₂Cl₂ was added over a period of 5 min. The reaction mixture was stirred an additional 30 min at 0°C then allowed to warm to room temperature and stirring was continued overnight. The reaction was again cooled to 0°C and quenched by addition of 1.0 mL water. The organic layer was separated and then washed with 2 N NaOH. The aqueous extracts were acidified with 1 N HCl and extracted with ether. The organic extracts were combined, washed with brine, dried (MgSO₄), filtered and evaporated *in vacuo*. The residue was purified on a silica gel flash chromatography column eluted with 5% EtOAc-hexane. Evaporation of the purified fractions and drying *in vacuo* afforded the title compound.

Step E: 2-Chloro-N-[2-hydroxy-4,6-bis(trichlorovinyl)benzyl]acetamide

A mixture of 0.352 g (1.0 mmol) of the product of Step D and 123.5 g (1.0 mmol) of *N*-hydroxymethyl-2-chloroacetamide was added in portions to a vigorously stirred solution of 0.9 mL acetic acid and 0.1 mL (98%) sulfuric acid at 0-10°C. The reaction mixture was allowed to warm to room temperature, and stirring was maintained for a total of 4 days. The reaction mixture was poured into ice-water, neutralized with saturated aqueous NaHCO₃ solution and extracted into CH₂Cl₂. The organic extracts were combined, washed with brine, dried (Na₂SO₄), filtered and evaporated. The residue was purified on a silica gel flash chromatography column eluted with 5-10% EtOAc in hexane. Evaporation of the purified fractions and drying *in vacuo* afforded the title compound.

Step F: 2-(Aminomethyl)-3,5-bis(trichlorovinyl)phenol

To a solution of 0.2 mL ethanol and 60 μ L conc. hydrochloric acid was added 0.025 g (0.05 mmol) of the product of Step E and the reaction mixture was stirred and heated to 85°C using an external oil bath overnight. The reaction mixture was then cooled to room temperature and evaporated *in vacuo*. The residue was triturated with ether and dried overnight *in vacuo* to afford the title compound as a white crystalline solid. HPLC/MS: 381.9 (M+1), 364.8 [(M+1)-NH₃]; R_t = 2.6 min.

21058PV

EXAMPLE 64**3,5-Bis(trichlorovinyl)-2-[ethylamino)methyl]phenol**

Using the procedure described in Example 2, the product of Step E in Example 53 was reduced with lithium aluminum hydride to afford the title compound.

5 HPLC/MS: 409.8 (M+1); R_t = 2.9 min.

Plasmodium Falciparum Assay In Vitro (PFAIV)

The PFAIV assay is an in vitro assay designed to identify potential inhibitors of *Plasmodium falciparum* by measuring the incorporation of tritiated 10 hypoxanthine into parasitized red blood cells.

The following method is an adaptation of the method described by Desjardins, RE et al, 1979. AAC Vol 16 p710-718:


1. Sixty microliters of a solution of RPMI 1640 media plus (1:100 dilution) gentamycin containing desired concentration of test compound is added to the wells of a 96-well plate. (For titrations, 120 microliters is added to the top well and the compounds are serially diluted into 60 microliters of media.)
2. Fifty three microliters of parasitized red blood cells is added to the wells. The parasitemia of the culture is approximately 2-3% and the hematocrit is 5%. The red blood cells are diluted in RPMI1640 media containing 20% human A+ serum and gentamycin.
3. Twelve microliters of RPMI1640 media containing 200 μ Ci (1:25 dilution of 25 1 μ Ci/ml solution) is added to each well.
4. The plates are incubated at 37% for 48 hours under reduced CO₂ conditions (candle jar). After incubation, the plates are frozen overnight, then thawed and harvested on a manual 96-well harvester onto Unifilter GF/B plates.
- 30 5. The plates are counted on a Wallac microbeta and % inhibition of parasite growth is determined as compared to control wells containing no compound.

The compounds of this invention have IC50 of \leq 1 ug/ml.

21058PV

WHAT IS CLAIMED IS:

1. A compound of formula I;



5 wherein,

R⁵, R^{1a} and R¹ independently are hydrogen, C₁₋₆ alkyl, halo, C₁₋₆ alkoxy, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, and trihalovinyl, said aryl optionally substituted with 1-3 groups of R^a;

10 R² is hydrogen, C₁₋₆ alkyl, and C₃₋₁₀ cycloalkyl; taken together with any intervening atoms can form a 3 to 7 membered carbocyclic or heterocyclic ring saturated or unsaturated, said heterocyclic ring containing 1-2 heteroatoms independently chosen from O, C(O), S, SO, SO₂, N, or NR^{2a} and optionally substituted by 1-3 R^a groups;

15 R^{2a} is hydrogen, and C₁₋₆ alkyl;

20 R³ and R^{3a} are independently hydrogen, halo, C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, and C₆₋₁₀ aryl, said aryl and alkyl optionally substituted with 1-3 groups of R^a; or

25 R³ and R^{3a} taken together with any intervening atoms can form a 3 to 7 membered carbocyclic or heterocyclic ring saturated or unsaturated, said heterocyclic ring containing 1-2 heteroatoms independently chosen from O, C(O), S, SO, SO₂, N, or NR^{2a} and optionally substituted by 1-3 R^a groups;

R⁴ is hydrogen, halo, C₁₋₆ alkyl, and trihaloalkyl;

30 R^a represents C₁₋₆ alkoxy, C₁₋₆ alkyl, CF₃, nitro, amino, cyano, C₁₋₆ alkylamino, or halogen; and

21058PV

n represents 1-3;

or a pharmaceutically acceptable salt, enantiomer, or diasteriomer thereof.

5 2. A compound according to claim 1 wherein R^{1a} and R¹ independently are hydrogen, tert-butyl, 1,2,2-trichlorovinyl, or phenyl .

10 3. A compound according to claim 1 wherein R² is hydrogen or C₁₋₄ alkyl, and n is 1.

15 4. A compound according to claim 1 wherein R^{1a} and R¹ independently are hydrogen, tert-butyl, 1,2,2-trichlorovinyl, or phenyl; R² is hydrogen or C₁₋₄ alkyl, and n is 1.

20 5. A compound according to claim 4 wherein R^{1a} and R¹ are tert-butyl, and R² is hydrogen.

25 6. A compound which is:

2-aminomethyl-5-tert-butyl-3-phenylphenol,

20 2-aminomethyl-5-tert-butyl-3-(4-methylphenyl)phenol,

3,5-di-tert-butyl-2-[(ethylamino)methyl]phenol,

3,5-di-tert-butyl-2-[1-(ethylamino)ethyl]phenol,

3,5-di-tert-butyl-2-[(methylamino)methyl]phenol,

3,5-bis(trichlorovinyl)-2-[(ethylamino)methyl]phenol,

25 3,5-di-tert-butyl-2-[(propylamino)methyl]phenol,

2-[(ethylamino)methyl]-5-(trichlorovinyl)phenol,

3,5-di-tert-butyl-2-[(butylamino)methyl]phenol,

3,5-di-tert-butyl-2-[(cyclohexylamino)methyl]phenol,

3,5-di-tert-butyl-2-[(hexylamino)methyl]phenol,

30 3,5-di-tert-butyl-2-[(octylamino)methyl]phenol,

3,5-di-tert-butyl-2-[(2-hydroxyethylamino)methyl]phenol,

tert-butyl N-(2,4-di-tert-butyl-6-hydroxybenzyl)-beta-alaninate,

3,5-di-tert-butyl-2-[(2-dimethylaminoethylamino)methyl]phenol,

3,5-di-tert-butyl-2-[(3-phenylpropylamino)methyl]phenol,

35 3,5-di-tert-butyl-2-[(2-phenylethylamino)methyl]phenol,

21058PV

- 3,5-di-tert-butyl-2-[(allylamino)methyl]phenol,
5-tert-butyl-2-[(ethylamino)methyl]phenol,
2-[(benzylamino)methyl]-5-tert-butylphenol,
2-[(cyclohexylamino)methyl]-5-(trichlorovinyl)phenol,
5 5-tert-butyl-2-{[(2-phenylethyl)amino]methyl}phenol,
2-[(benzylamino)methyl]-5-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-[(decylamino)methyl]phenol,
2-[(propylamino)methyl]-5-(trichlorovinyl)phenol,
5-tert-butyl-2-[(propylamino)methyl]phenol,
10 5-tert-butyl-2-[(cyclopropylamino)methyl]phenol,
5-tert-butyl-2-[(1,2,3,4-tetrahydronaphthalen-1-ylamino)methyl]phenol,
2-[(cyclopropylamino)methyl]-5-(trichlorovinyl)phenol,
2-[(isopropylamino)methyl]-5-(trichlorovinyl)phenol,
2-[(1,2,3,4-tetrahydronaphthalen-1-ylamino)methyl]-5-(trichlorovinyl)phenol,
15 2-[(2,3-dihydro-1H-inden-1-ylamino)methyl]-5-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-{{[(1R)-1-phenylethyl]amino}methyl}phenol,
3,5-di-tert-butyl-2-{{[(1-naphthylmethyl)amino]methyl}phenol,
3,5-di-tert-butyl-2-{{[(2-naphthylmethyl)amino]methyl}phenol,
2-[(tert-butylamino)methyl]-5-(trichlorovinyl)phenol,
20 3,5-di-tert-butyl-2-[(1,2,3,4-tetrahydronaphthalen-2-ylamino)methyl]phenol,
2-[(cyclohexylamino)methyl]-3-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-[(2,3-dihydro-1H-inden-2-ylamino)methyl]phenol,
3,5-di-tert-butyl-2-{{[(1R)-2,3-dihydro-1H-inden-1-ylamino]methyl}phenol,
3,5-di-tert-butyl-2-{{[(1S)-2,3-dihydro-1H-inden-1-ylamino]methyl}phenol,
25 5-tert-butyl-2-[(2,3-dihydro-1H-inden-2-ylamino)methyl]phenol,
5-tert-butyl-2-{{[(4-methoxybenzyl)amino]methyl}phenol,
5-tert-butyl-2-[(neopentylamino)methyl]phenol,
5-tert-butyl-2-{{[(3,3-dimethylbutyl)amino]methyl}phenol,
5-tert-butyl-2-[(cyclohexylamino)ethyl]phenol,
30 5-tert-butyl-2-[(2,3-dihydro-1H-inden-1-ylamino)methyl]phenol,
5-tert-butyl-2-[(isopropylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(decahydronaphthalen-2-ylamino)methyl]phenol,
5-tert-butyl-2-[(isopentylamino)methyl]phenol,
5-tert-butyl-2-[(isobutylamino)methyl]phenol,
35 3,5-di-tert-butyl-2-{{[(2-pyridin-2-ylethyl)amino]methyl}phenol,

21058PV

- 3,5-di-tert-butyl-2-{[(2-pyridin-3-ylethyl)amino]methyl}phenol,
 3,5-di-tert-butyl-2-{[(2-pyridin-4-ylethyl)amino]methyl}phenol,
 3,5-di-tert-butyl-2-[(tetrahydro-2H-pyran-4-ylamino)methyl]phenol,
 3,5-di-tert-butyl-2-{[(cyclohexylmethyl)amino]methyl}phenol,
 5 5-tert-butyl-2-{[(3-methoxybenzyl)amino]methyl}phenol,
 2-(aminomethyl)-4-bromo-5-tert-butylphenol,
 ethyl N-(2,4-ditert-butyl-6-hydroxybenzyl)-beta-alaninate,
 3-tert-butyl-2-(piperidin-1-ylmethyl)phenol,
 3-tert-butyl-2-[(cyclohexylamino)methyl]phenol,
 10 2-[2-(cyclohexylamino)ethyl]-5-(trichlorovinyl)phenol,
 3-tert-butyl-2-[2-(cyclohexylamino)ethyl]phenol,
 3,5-di-tert-butyl-2-{[(tetrahydro-2H-pyran-2-ylmethyl)amino]methyl}phenol,
 3,5-di-tert-butyl-2-[2-(cyclohexylamino)ethyl]phenol,
 3,5-di-tert-butyl-2-{[(3-furylmethyl)amino]methyl}phenol, or
 15 2-[2-(benzylamino)ethyl]-3,5-ditert-butylphenol,
 or pharmaceutically acceptable salts thereof.

7. A composition comprising a compound of claim 1 and a pharmaceutically acceptable salt thereof.
 20
 8. A composition comprising a compound of claim 6 and a pharmaceutically acceptable salt thereof.

9. A method for the treatment of malaria which comprises
 25 administering to a patient in need of such treatment a compound of formula I:



wherein,

21058PV

R₅, R_{1a} and R₁ independently are hydrogen, C₁₋₆ alkyl, halo, C₁₋₆ alkoxy, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, and trihalovinyl, said aryl optionally substituted with 1-3 groups of R^a;

5 R₂ is hydrogen, C₁₋₆ alkyl, and C₃₋₁₀ cycloalkyl; taken together with any intervening atoms can form a 3 to 7 membered carbocyclic or heterocyclic ring saturated or unsaturated, said heterocyclic ring containing 1-2 heteroatoms independently chosen from O, C(O), S, SO, SO₂, N, or NR_{2a} and optionally substituted by 1-3 R^a groups;

10 R_{2a} is hydrogen, and C₁₋₆ alkyl;

R₃ and R_{3a} are independently hydrogen, halo, C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, and C₆₋₁₀ aryl, said aryl and alkyl optionally substituted with 1-3 groups of R^a; or

15 R₃ and R_{3a} taken together with any intervening atoms can form a 3 to 7 membered carbocyclic or heterocyclic ring saturated or unsaturated, said heterocyclic ring containing 1-2 heteroatoms independently chosen from O, C(O), S, SO, SO₂, N, or NR^{2a} and optionally substituted by 1-3 R^a groups;

20 R⁴ is hydrogen, halo, C₁₋₆ alkyl, and trihaloalkyl;

R^a represents C₁₋₆ alkoxy, C₁₋₆ alkyl, CF₃, nitro, amino, cyano, C₁₋₆ alkylamino, or halogen; and

25 n represents 1-3;
or a pharmaceutically acceptable salt, enantiomer, or diasteriomer thereof.

10. A method according to claim 9 wherein R_{1a} and R₁
30 independently are hydrogen, tert-butyl, 1,2,2-trichlorovinyl, or phenyl .

11. A method according to claim 9 wherein R₂ is hydrogen or C₁₋₄ alkyl, and n is 1.

21058PV

12. A method according to claim 9 wherein R^{1a} and R¹ independently are hydrogen, tert-butyl, 1,2,2-trichlorovinyl, or phenyl; R² is hydrogen or C₁₋₄ alkyl, and n is 1.

13. A method according to claim 12 wherein R^{1a} and R¹ are tert-butyl, and R² is hydrogen.

14. A method according to claim 9 wherein the compound is :

- 2-aminomethyl-5-tert-butyl-3-phenylphenol,
- 2-aminomethyl-5-tert-butyl-3-(4-methylphenyl)phenol,
- 10 3,5-di-tert-butyl-2-[(ethylamino)methyl]phenol,
- 3,5-di-tert-butyl-2-[1-(ethylamino)ethyl]phenol,
- 3,5-di-tert-butyl-2-[(methylamino)methyl]phenol,
- 3,5-bis(trichlorovinyl)-2-[(ethylamino)methyl]phenol,
- 3,5-di-tert-butyl-2-[(propylamino)methyl]phenol,
- 15 2-[(ethylamino)methyl]-5-(trichlorovinyl)phenol,
- 3,5-di-tert-butyl-2-[(butylamino)methyl]phenol,
- 3,5-di-tert-butyl-2-[(cyclohexylamino)methyl]phenol,
- 3,5-di-tert-butyl-2-[(hexylamino)methyl]phenol,
- 3,5-di-tert-butyl-2-[(octylamino)methyl]phenol,
- 20 3,5-di-tert-butyl-2-[(2-hydroxyethylamino)methyl]phenol,
tert-butyl N-(2,4-di-tert-butyl-6-hydroxybenzyl)-beta-alaninate,
- 3,5-di-tert-butyl-2-[(2-dimethylaminoethylamino)methyl]phenol,
- 3,5-di-tert-butyl-2-[(3-phenylpropylamino)methyl]phenol,
- 3,5-di-tert-butyl-2-[(2-phenylethylamino)methyl]phenol,
- 25 3,5-di-tert-butyl-2-[(allylamino)methyl]phenol,
- 5-tert-butyl-2-[(ethylamino)methyl]phenol,
- 2-[(benzylamino)methyl]-5-tert-butylphenol,
- 5-tert-butyl-2-[(cyclohexylamino)methyl]phenol,
- 2-[(cyclohexylamino)methyl]-5-(trichlorovinyl)phenol,
- 30 5-tert-butyl-2-{{(2-phenylethyl)amino}methyl}phenol,
- 2-[(benzylamino)methyl]-5-(trichlorovinyl)phenol,
- 3,5-di-tert-butyl-2-[(decylamino)methyl]phenol,
- 2-[(propylamino)methyl]-5-(trichlorovinyl)phenol,
- 5-tert-butyl-2-[(propylamino)methyl]phenol,

21058PV

- 5-tert-butyl-2-[(cyclopropylamino)methyl]phenol,
5-tert-butyl-2-[(1,2,3,4-tetrahydronaphthalen-1-ylamino)methyl]phenol,
2-[(cyclopropylamino)methyl]-5-(trichlorovinyl)phenol,
2-[(isopropylamino)methyl]-5-(trichlorovinyl)phenol,
5 2-[(1,2,3,4-tetrahydronaphthalen-1-ylamino)methyl]-5-(trichlorovinyl)phenol,
2-[(2,3-dihydro-1H-inden-1-ylamino)methyl]-5-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-{{(1R)-1-phenylethyl}amino}methylphenol,
3,5-di-tert-butyl-2-{{(1-naphthylmethyl)amino}methyl}phenol,
3,5-di-tert-butyl-2-{{(2-naphthylmethyl)amino}methyl}phenol,
10 2-[(tert-butylamino)methyl]-5-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-[(1,2,3,4-tetrahydronaphthalen-2-ylamino)methyl]phenol,
2-[(cyclohexylamino)methyl]-3-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-[(2,3-dihydro-1H-inden-2-ylamino)methyl]phenol,
3,5-di-tert-butyl-2-{{(1R)-2,3-dihydro-1H-inden-1-ylamino}methyl}phenol,
15 3,5-di-tert-butyl-2-{{(1S)-2,3-dihydro-1H-inden-1-ylamino}methyl}phenol,
5-tert-butyl-2-[(2,3-dihydro-1H-inden-2-ylamino)methyl]phenol,
5-tert-butyl-2-{{(4-methoxybenzyl)amino}methyl}phenol,
5-tert-butyl-2-[(neopentylamino)methyl]phenol,
5-tert-butyl-2-{{(3,3-dimethylbutyl)amino}methyl}phenol,
20 5-tert-butyl-2-[2-(cyclohexylamino)ethyl]phenol,
5-tert-butyl-2-[(2,3-dihydro-1H-inden-1-ylamino)methyl]phenol,
5-tert-butyl-2-[(isopropylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(decahydronaphthalen-2-ylamino)methyl]phenol,
5-tert-butyl-2-[(isopentylamino)methyl]phenol,
25 5-tert-butyl-2-[(isobutylamino)methyl]phenol,
5-tert-butyl-2-(piperidin-1-ylmethyl)phenol,
3,5-di-tert-butyl-2-{{(2-pyridin-2-ylethyl)amino}methyl}phenol,
3,5-di-tert-butyl-2-{{(2-pyridin-3-ylethyl)amino}methyl}phenol,
3,5-di-tert-butyl-2-{{(2-pyridin-4-ylethyl)amino}methyl}phenol,
30 3,5-di-tert-butyl-2-[(tetrahydro-2H-pyran-4-ylamino)methyl]phenol,
3,5-di-tert-butyl-2-{{(cyclohexylmethyl)amino}methyl}phenol,
2-(aminomethyl)-3,5-di-tert-butylphenol,
5-tert-butyl-2-{{(3-methoxybenzyl)amino}methyl}phenol,
2-(aminomethyl)-4-bromo-5-tert-butylphenol,
35 ethyl N-(2,4-ditert-butyl-6-hydroxybenzyl)-beta-alaninate,

21058PV

- 3-tert-butyl-2-(piperidin-1-ylmethyl)phenol,
3-tert-butyl-2-[(cyclohexylamino)methyl]phenol,
2-[2-(cyclohexylamino)ethyl]-5-(trichlorovinyl)phenol,
3-tert-butyl-2-[2-(cyclohexylamino)ethyl]phenol,
5 3,5-di-tert-butyl-2-{{(tetrahydro-2H-pyran-2-ylmethyl)amino}methyl}phenol,
3,5-di-tert-butyl-2-[2-(cyclohexylamino)ethyl]phenol,
3,5-di-tert-butyl-2-{{(3-furylmethyl)amino}methyl}phenol, or
2-[2-(benzylamino)ethyl]-3,5-ditert-butylphenol,
and pharmaceutically acceptable salts thereof.
- 10 15. A method according to claim 9 wherein a second anti-malarial agent is administered said second anti-malarial agent selected from the group consisting of Chloroquine, Fansidar, Amodiaquine, Quinine, Halofantrine, Mefloquine, Artemether/Artesunate and Malarone.

21058PV

ABSTRACT OF THE INVENTION

AMINOALKYLPHENOLS, METHODS OF USING AND MAKING THE SAME

The present invention relates to Mannich base antimalarial aminoalkylphenol compounds and their use against protozoa of the genus 5 *Plasmodium*, particularly emerging strains of drug-resistant *Plasmodia*. This invention further relates to compositions containing such compounds and a process for making the compounds. This and other aspects of the invention are realized upon review of the entire specification.

10

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.